Denali's $1.1 Billion Rainy Day Fund Meets AVLAYAH's $3.6 Million Start

Denali's cash cushion buys time, but AVLAYAH's early revenue sets the real test

Denali now has more than $1.1 billion in cash, but AVLAYAH's $3.6 million start will help determine whether that balance sheet buys meaningful time or merely pushes back future pressure. In AVLAYAH's first full commercial quarter, Denali reported $3.6 million in net product revenue, and the company also received $195 million from the sale of a Priority Review Voucher. That brought pro forma cash, cash equivalents, and marketable securities to more than $1.1 billion.

What matters now is not just the cash pile. Investors also need evidence that the launch can move from an early start to repeating patient volumes and a stronger commercial run-rate.

The bear case is straightforward: a rare-disease launch can be small at first, and a $3.6 million quarter may look more like the beginning of a business than the final scorecard. Investors will also want to see whether Denali can keep spending to build commercial infrastructure while still advancing the rest of the pipeline. Cash buys time; it does not create value by itself.

The bull case is that the launch may still be early. Management said early launch indicators were stronger than anticipated, and the cash cushion can support broader access, patient onboarding, and pipeline execution while the commercial machine matures. The core question is whether Denali can turn that runway into durable revenue growth.

AVLAYAH has the story, but access and conversion now drive the valuation debate

AVLAYAH already has a clear reason to exist as the first new FDA-approved therapy in nearly 20 years for Hunter syndrome. It is also strategically important as the first approved medicine developed using our Transport Vehicle platform, and that platform narrative extends into two Alzheimer's disease programs now in clinical development. Still, the next valuation hinge is less about scientific proof and more about whether the commercial business can generate repeatable patient starts and revenue.

Why access, not science, likely drives the next rerating

The business logic is simple. In a rare disease, revenue does not wait for every eligible patient to be identified. It rises as coverage expands, prescriptions become easier to fill, and care teams can onboard patients more efficiently. That is why Denali's expectation of $10 million to $12 million in third-quarter revenue matters. Investors are looking for evidence that access is translating into a growing commercial run-rate, not just a strong opening headline.

Bull versus bear: conversion speed matters more than disease size

Bears can point to Denali's estimate of roughly 375 eligible U.S. pediatric patients. That is a limited pool, and it caps how far revenue can go if conversion stays slow.

Bulls have the stronger near-term case if conversion keeps improving. Published payer coverage already exceeds 50% of covered lives, which means Denali does not need to build access from scratch. The key test is whether newly covered patients are moving onto treatment quickly enough to make AVLAYAH look like an operating business rather than a one-quarter milestone.

What investors should watch next quarter

Investors should focus on a short list of operating signals that show whether coverage is becoming patient volume:

• whether third-quarter revenue lands in or near the $10 million to $12 million range
• whether payer coverage continues to broaden
• whether patient onboarding is accelerating beyond the initially engaged families

If those signals connect, valuation can shift from promising start to real business. If they do not, AVLAYAH will still matter, but the market may keep treating it as an important milestone rather than a scaling asset.

The key question for the next quarter is simple: are the newly covered lives becoming new patients on treatment?